BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 26392546)

  • 1. Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.
    Lu Y; Chan W; Ko BY; VanLang CC; Swartz JR
    Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12360-5. PubMed ID: 26392546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles.
    Dishlers A; Skrastina D; Renhofa R; Petrovskis I; Ose V; Lieknina I; Jansons J; Pumpens P; Sominskaya I
    Mol Biotechnol; 2015 Dec; 57(11-12):1038-49. PubMed ID: 26446016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers.
    Skrastina D; Bulavaite A; Sominskaya I; Kovalevska L; Ose V; Priede D; Pumpens P; Sasnauskas K
    Vaccine; 2008 Apr; 26(16):1972-81. PubMed ID: 18343539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications.
    Strods A; Ose V; Bogans J; Cielens I; Kalnins G; Radovica I; Kazaks A; Pumpens P; Renhofa R
    Sci Rep; 2015 Jun; 5():11639. PubMed ID: 26113394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.
    Hyakumura M; Walsh R; Thaysen-Andersen M; Kingston NJ; La M; Lu L; Lovrecz G; Packer NH; Locarnini S; Netter HJ
    J Virol; 2015 Nov; 89(22):11312-22. PubMed ID: 26339047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Expression of Tandem-HBc Virus-Like Particles (VLPs).
    Stephen SL; Beales L; Peyret H; Roe A; Stonehouse NJ; Rowlands DJ
    Methods Mol Biol; 2018; 1776():97-123. PubMed ID: 29869237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen.
    Pleckaityte M; Bremer CM; Gedvilaite A; Kucinskaite-Kodze I; Glebe D; Zvirbliene A
    BMC Biotechnol; 2015 Sep; 15():85. PubMed ID: 26370129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
    Mulder AM; Carragher B; Towne V; Meng Y; Wang Y; Dieter L; Potter CS; Washabaugh MW; Sitrin RD; Zhao Q
    PLoS One; 2012; 7(4):e33235. PubMed ID: 22493667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the immunogenicity of virus-like particles composed of mutant hepatitis B virus envelope subunits.
    Cheong WS; Hyakumura M; Yuen L; Warner N; Locarnini S; Netter HJ
    Antiviral Res; 2012 Feb; 93(2):209-218. PubMed ID: 22138713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of HBc virus-like particles as modular nanocarrier by intein-mediated trans-splicing.
    Wang Z; Tang S; Yue N; Qian Z; Zhou S
    Biochem Biophys Res Commun; 2021 Jan; 534():891-895. PubMed ID: 33213839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity.
    Joe CCD; Chatterjee S; Lovrecz G; Adams TE; Thaysen-Andersen M; Walsh R; Locarnini SA; Smooker P; Netter HJ
    Vaccine; 2020 May; 38(22):3892-3901. PubMed ID: 32284273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
    Skrastina D; Petrovskis I; Lieknina I; Bogans J; Renhofa R; Ose V; Dishlers A; Dekhtyar Y; Pumpens P
    PLoS One; 2014; 9(12):e114006. PubMed ID: 25436773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.
    Sazegari S; Akbarzadeh Niaki M; Afsharifar A; Niazi A; Derakhshandeh A; Moradi Vahdat M; Hemmati F; Eskandari MH
    Microb Cell Fact; 2023 Feb; 22(1):39. PubMed ID: 36841778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine.
    Yin Y; Zhang S; Cai C; Zhang J; Dong D; Guo Q; Fu L; Xu J; Chen W
    Immunobiology; 2014 Feb; 219(2):97-103. PubMed ID: 24054942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modularized peptides modified HBc virus-like particles for encapsulation and tumor-targeted delivery of doxorubicin.
    Shan W; Zhang D; Wu Y; Lv X; Hu B; Zhou X; Ye S; Bi S; Ren L; Zhang X
    Nanomedicine; 2018 Apr; 14(3):725-734. PubMed ID: 29275067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice.
    Huang Z; Santi L; LePore K; Kilbourne J; Arntzen CJ; Mason HS
    Vaccine; 2006 Mar; 24(14):2506-13. PubMed ID: 16417953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing stability and assembly of the hepatitis B surface antigen into virus-like particles during down-stream processing.
    Zahid M; Lünsdorf H; Rinas U
    Vaccine; 2015 Jul; 33(31):3739-45. PubMed ID: 26079614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris.
    Freivalds J; Dislers A; Ose V; Pumpens P; Tars K; Kazaks A
    Protein Expr Purif; 2011 Feb; 75(2):218-24. PubMed ID: 20854910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.